Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.

Cakir A, Gonul II, Uluoglu O.

Diagn Pathol. 2012 Oct 20;7:145. doi: 10.1186/1746-1596-7-145.

PMID:
23082819
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Metaplastic breast carcinomas and their relationship with basal-like phenotype.

Cakir A, Gönül II, Uluoğlu O.

Turk Patoloji Derg. 2012;28(2):134-41. doi: 10.5146/tjpath.2012.01112.

PMID:
22627631
[PubMed - indexed for MEDLINE]
Free Article
3.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

PMID:
16341146
[PubMed - indexed for MEDLINE]
Free Article
4.

P-cadherin and vimentin are useful basal markers in breast cancers.

Tsang JY, Au SK, Ni YB, Shao MM, Siu WM, Hui SW, Chan SK, Chan KW, Kwok YK, Chan KF, Tse GM.

Hum Pathol. 2013 Dec;44(12):2782-91. doi: 10.1016/j.humpath.2013.07.029. Epub 2013 Oct 16.

PMID:
24139214
[PubMed - indexed for MEDLINE]
5.

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO.

J Pathol. 2006 Mar;208(4):495-506.

PMID:
16429394
[PubMed - indexed for MEDLINE]
6.

Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.

Tsang JY, Wong KH, Lai MW, Lacambra MD, Ko CW, Chan SK, Lam CC, Yu AM, Tan PH, Tse GM.

J Clin Pathol. 2013 Apr;66(4):291-6. doi: 10.1136/jclinpath-2012-201027. Epub 2012 Dec 25.

PMID:
23268325
[PubMed - indexed for MEDLINE]
7.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
[PubMed - indexed for MEDLINE]
8.

Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.

Laé M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A.

Mod Pathol. 2009 Feb;22(2):291-8. doi: 10.1038/modpathol.2008.184. Epub 2008 Nov 14.

PMID:
19011601
[PubMed - indexed for MEDLINE]
Free Article
9.

A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.

Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C.

Mod Pathol. 2012 Apr;25(4):556-66. doi: 10.1038/modpathol.2011.194. Epub 2011 Dec 16.

PMID:
22173289
[PubMed - indexed for MEDLINE]
Free Article
10.

Mesothelial markers in high-grade breast carcinoma.

Duhig EE, Kalpakos L, Yang IA, Clarke BE.

Histopathology. 2011 Nov;59(5):957-64. doi: 10.1111/j.1365-2559.2011.04036.x.

PMID:
22092407
[PubMed - indexed for MEDLINE]
11.

Cytologic features of triple-negative breast carcinoma.

Bonzanini M, Morelli L, Bonandini EM, Leonardi E, Pertile R, Dalla Palma P.

Cancer Cytopathol. 2012 Dec 25;120(6):401-9. doi: 10.1002/cncy.21207. Epub 2012 Jul 25.

PMID:
22833438
[PubMed - indexed for MEDLINE]
12.

Fine-needle aspiration cytology of triple-negative basal-like breast cancer.

Akashi S, Kuwabara H, Kurisu Y, Takahashi Y, Yasuda E, Takeshita A, Ishizaki S, Tsuji M, Shibayama Y.

Diagn Cytopathol. 2013 Apr;41(4):283-7. doi: 10.1002/dc.21807. Epub 2011 Oct 11.

PMID:
21987494
[PubMed - indexed for MEDLINE]
13.

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Bryan BB, Schnitt SJ, Collins LC.

Mod Pathol. 2006 May;19(5):617-21.

PMID:
16528377
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
[PubMed - indexed for MEDLINE]
15.

Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients.

Carvalho FM, Bacchi LM, Santos PP, Bacchi CE.

Clinics (Sao Paulo). 2010;65(10):1033-6.

PMID:
21120307
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Clinicopathologic characteristics of breast cancer with basal-like immunophenotype].

Wu WX, Han WL, Zhang YP, Yu QX, Wen XW, Lu N, Tang ZY, Yuan LN, Zhang Y, Wang Z, Wang W, Yang HJ, Chen CP, Guo WL.

Zhonghua Bing Li Xue Za Zhi. 2008 Nov;37(11):743-8. Chinese.

PMID:
19094708
[PubMed - indexed for MEDLINE]
17.

Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE.

J Clin Pathol. 2006 Jul;59(7):729-35. Epub 2006 Mar 23.

PMID:
16556664
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.

Lin Fde M, Pincerato KM, Bacchi CE, Baracat EC, Carvalho FM.

J Clin Pathol. 2012 Jan;65(1):64-8. doi: 10.1136/jclinpath-2011-200318. Epub 2011 Oct 29.

PMID:
22039288
[PubMed - indexed for MEDLINE]
19.

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Dabbs DJ, Chivukula M, Carter G, Bhargava R.

Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

PMID:
16941011
[PubMed - indexed for MEDLINE]
Free Article
20.

Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast.

Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH.

Mod Pathol. 2010 Oct;23(10):1357-63. doi: 10.1038/modpathol.2010.123. Epub 2010 Jun 25.

PMID:
20581807
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk